Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial

Clinical Trial

doi: 10.1111/j.1464-5491.2005.01473.x.

S Pampanelli, F Porcellati, A Avogaro, E Bosi, G Petrella, S Squatrito, S Furneri, G Marra, L Vitali, M Previti, D Cucinotta

Affiliations

PMID: 15842516
DOI: 10.1111/j.1464-5491.2005.01473.x

Clinical Trial

G Perriello et al. Diabet Med. 2005 May.

Abstract

Aims: This randomized, multi-centre, double-blind, stratified, two period, cross-over trial was undertaken to assess the pharmacokinetics and pharmacodynamics of insulin aspart injected immediately before compared with regular human insulin injected 30 min before a Mediterranean-style meal in 37 (23 M, 14 F) patients with Type 2 diabetes.

Methods: Insulin aspart or regular human insulin was given subcutaneously (0.15 U/kg) in random sequence, using a double-dummy technique (at one visit: human regular insulin at t=-30 min and placebo at t=0; at the other visit: placebo at t=-30 min and aspart insulin at t=0). Serum glucose and insulin concentrations (15 points) were measured after each meal for 240 min.

Results: Post-prandial glycaemic excursions were 20% lower with insulin aspart (IAsp) compared with regular human insulin (HI) treatment [ratio (Iasp/HI)=0.80, CI=(0.66-0.98), P=0.034]. The maximum serum glucose (SG) concentration was similar for the two treatments (P=NS). The (median) time to maximum SG was 25 min shorter for IAsp compared with HI (P=0.048). Maximum serum insulin concentration was higher after IAsp compared with HI (P=0.023) as well as the area under the 4-h serum insulin curve (P=0.006). Furthermore, the time to maximum serum insulin concentration was 27 min shorter after IAsp (P=0.039), even though IAsp was injected 30 min after HI. No adverse events occurred during the trial.

Conclusions: In patients with Type 2 diabetes a more favourable insulin profile and a better glycaemic control were found with IAsp injected immediately before compared with HI injected 30 min before a Mediterranean-style meal.

PubMed Disclaimer

Cited by

Safety and effectiveness of insulin aspart in Basal-bolus regimens regardless of age: a1chieve study results.
Latif ZA, Hussein Z, Litwak L, El Naggar N, Chen JW, Soewondo P. Latif ZA, et al. Diabetes Ther. 2013 Jun;4(1):103-18. doi: 10.1007/s13300-013-0023-1. Epub 2013 May 14. Diabetes Ther. 2013. PMID: 23670205 Free PMC article.
IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts.
Eckardt K, May C, Koenen M, Eckel J. Eckardt K, et al. Diabetologia. 2007 Dec;50(12):2534-43. doi: 10.1007/s00125-007-0815-9. Epub 2007 Sep 18. Diabetologia. 2007. PMID: 17898992
Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations.
Muchmore DB, Vaughn DE. Muchmore DB, et al. J Diabetes Sci Technol. 2010 Mar 1;4(2):419-28. doi: 10.1177/193229681000400223. J Diabetes Sci Technol. 2010. PMID: 20307403 Free PMC article. Review.
Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study.
Hövelmann U, Raiter Y, Chullikana A, Liu M, Donnelly C, Lawrence T, Sengupta N, Cl G, Ranganna G, Barve A. Hövelmann U, et al. Diabetes Obes Metab. 2021 Dec;23(12):2670-2678. doi: 10.1111/dom.14519. Epub 2021 Aug 25. Diabetes Obes Metab. 2021. PMID: 34378861 Free PMC article. Clinical Trial.
Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus.
Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, Gerlach FM. Fullerton B, et al. Cochrane Database Syst Rev. 2018 Dec 17;12(12):CD013228. doi: 10.1002/14651858.CD013228. Cochrane Database Syst Rev. 2018. PMID: 30556900 Free PMC article.

Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial - PubMed (original) (raw)